Transcription Factors
Transcription factors (TFs) are key cellular components that control the first step of gene expression, the transcription of DNA into RNA sequences. By ensuring the correct expression of specific genes, the transcriptional regulatory system plays a central part in controlling many biological processes, ranging from cell cycle progression and maintenance of intracellular metabolic and physiological balance, to cellular differentiation and developmental time courses. TFs may be constitutively active or conditionally active. The most common classification of TFs is based on the structure of their DNA-binding domains. Grouping TFs by structural domain has been extremely useful in uncovering how they recognize and bind specific DNA sequences, as well as providing insights into their evolutionary histories. Moreover, in some instances the DNA-binding domain provides clues to their function[1]. A comprehensive classification recognizes four superfamilies with well-defined structural homology: basic domains TFs (1), Zinc-coordinating domains TFs (2), helix-turn-helix (HTH) domains TFs (3), and beta-scaffold domains with Minor Groove Contacts TFs (4). Additionally, a fifth family of orphan TFs exists for which no superclass assignment can be done yet because of lack of structural information[2].
[1] J.M. Vaquerizas et al. A census of human transcription factors: function, expression and evolution. Nat. Rev. Genetics 2009, 10, 252-263.
[2] P. Stegmaier, A.E. Kel, E. Wingender. SystematicDNA-binding domain classification of transcription factors. Genome Inform. 2004, 15, 276-286.
| Axon ID | Name | Description | From price | |
|---|---|---|---|---|
| 2319 | L 002 | Inhibitor of p300 HAT (KAT3B) and p53 acetylation | €80.00 | |
| 3270 | Lj-1-60 | Fyn inhibitor targeting the Fyn/Stat3 pathway | €90.00 | |
| 2480 | LW6 | Inhibitor of HIF-1α stability via MDH2 inhibition and/or binding with CHP1 | €85.00 | |
| 3607 | Micheliolide | NF-κB activation inhibitor | €120.00 | |
| 2733 | ML329 | Inhibitor of the MITF molecular pathway | €110.00 | |
| 2641 | ML334 | Activator of NRF2 by inhibition of Keap1-NRF2 interactions | €130.00 | |
| 2671 | ML385 | Inhibitor of NRF2 | €120.00 | |
| 3229 | MYCi975 | MYC inhibitor | €110.00 | |
| 2517 | Napabucasin | Oral first-in-class cancer stemness inhibitor that works by targeting STAT3 | €105.00 | |
| 3387 | NF-κB Activation Inhibitor IV | Potent NF-κB activation inhibitor | €90.00 | |
| 3031 | NIC3 | Inhibitor of nucleus accumbens-associated protein-1 (NAC1) homodimerization | €90.00 | |
| 2955 | NSC 228155 | EGFR tyrosine kinase activator; Inhibitor of KIX-KID interaction | €75.00 | |
| 2016 | NSC 319726 | Reactivator of the p53 mutant p53R175 | €95.00 | |
| 1402 | NSC 348884 | NPM inhibitor | €120.00 | |
| 2564 | NSC 59984 | Activator of p53 that restores WT p53 signaling via p73 activation | €95.00 | |
| 3277 | NSC194598 | p53 DNA-binding inhibitor | €130.00 | |
| 2651 | OAC2 | Oct4 and Nanog activating compound that enhances reprogramming efficiency | €60.00 | |
| 2497 | Omaveloxolone | Triterpenoid activator of NRF2 and inhibitor of NF-κB | €90.00 | |
| 3614 | Parthenolide | NF-κB activation inhibitor | €90.00 | |
| 1871 | Pifithrin-α hydrobromide | Inhibitor of p53 protein | €95.00 | |
| 3051 | Pifithrin-β | Inhibitor of p53 protein; Condensation product of Pifithrin-α | €95.00 | |
| 2488 | Piperlongumine | Natural alkaloid with potent cytotoxic activity | €65.00 | |
| 3480 | PY-60 | Specific YAP activator targeting ANXA2 | €150.00 | |
| 3520 | PY108 | Potent, orally bioavailable AHR agonist | €120.00 | |
| 3521 | PY109 | Potent, orally bioavailable AHR agonist | €120.00 | |
| 3061 | RBPJ inhibitor RIN1 | First-in-class, potent and selective RBPJ inhibitor | €120.00 | |
| 2313 | S3I 201 | Potent, cellular STAT3 inhibitor | €90.00 | |
| 2244 | SCH 529074 | Small molecule activator of mutant p53. | €120.00 | |
| 1701 | Shz-1 | Stem cell differentiating agent; Nkx2.5 inducer | €95.00 | |
| 2764 | SIS3 | Potent and selective inhibitor of Smad3 and TGF-βR1 signaling | €135.00 | |